SAN DIEGO--(BUSINESS WIRE)--Inovio Biomedical Corporation (AMEX:INO), a leader in enabling the development of DNA vaccines using electroporation-based DNA delivery, announced today that its partner, Tripep AB of Sweden, treated the first subject in a Phase I/II clinical trial of a novel DNA vaccine designed to treat chronically infected hepatitis C virus (HCV) patients. The clinical trial is designed to test Tripep’s proprietary DNA vaccine, ChronVac-C®, administered using Inovio’s MedPulser® DNA Delivery System, in 12 subjects already infected with HCV. The trial is being conducted in Sweden at two Karolinska University Hospitals, the Center for Gastroenterology in Solana and at the Infections Clinic in Huddinge.
